Table 1 Comparison of subtype classification between iRDM and PAM50 in four breast cancer datasets
From: An assessment of prognostic immunity markers in breast cancer
Method | Subtypes | Basal | HER2E | Immuno | Lum A | Lum B | Normal | Mixed* | Total | |
|---|---|---|---|---|---|---|---|---|---|---|
AFFY1951 | iRDM | counts | 310 | 211 | 342 | 441 | 351 | 209 | 87 | 1951 |
percent | 16% | 11% | 18% | 23% | 18% | 11% | 4% | 100% | ||
PAM50 | counts | 361 | 244 | NA | 490 | 368 | 232 | 256 | 1951 | |
percent | 19% | 13% | NA | 25% | 19% | 12% | 13% | 100% | ||
METABRIC | iRDM | counts | 298 | 208 | 383 | 425 | 387 | 199 | 97 | 1997 |
percent | 15% | 10% | 19% | 21% | 19% | 10% | 5% | 100% | ||
PAM50 | counts | 339 | 255 | NA | 428 | 410 | 253 | 312 | 1997 | |
percent | 17% | 13% | NA | 21% | 21% | 13% | 16% | 100% | ||
TCGA | iRDM | counts | 187 | 113 | 171 | 194 | 244 | 181 | 50 | 1140 |
percent | 16% | 10% | 15% | 17% | 21% | 16% | 4% | 100% | ||
PAM50 | counts | 207 | 140 | NA | 262 | 256 | 171 | 104 | 1140 | |
percent | 18% | 12% | NA | 23% | 22% | 15% | 9% | 100% | ||
TARGETSEQ | iRDM | counts | 112 | 49 | 80 | 120 | 55 | 41 | 26 | 483 |
percent | 23% | 10% | 16% | 25% | 11% | 9% | 5% | 100% | ||
PAM50 | counts | 128 | 64 | NA | 134 | 67 | 33 | 57 | 483 | |
percent | 26% | 13% | NA | 28% | 14% | 7% | 12% | 100% |
